Is Subcutaneous Bortezomib Ready for Prime Time?
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 73, doi. 10.1007/s11899-011-0078-x
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2011 AND VI 6 AND IP 2
Results: 11
1
2
New Immunomodulatory Drugs in Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 120, doi. 10.1007/s11899-011-0077-y
- By:
- Publication type:
- Article
3
New Drugs for Chronic Myelogenous Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 96, doi. 10.1007/s11899-011-0079-9
- By:
- Publication type:
- Article
4
Updates in Cytogenetics and Molecular Markers in MDS.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 126, doi. 10.1007/s11899-011-0081-2
- By:
- Publication type:
- Article
5
Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 113, doi. 10.1007/s11899-011-0080-3
- By:
- Publication type:
- Article
6
Chronic Myelogenous Leukemia: Monitoring Response to Therapy.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 75, doi. 10.1007/s11899-011-0082-1
- By:
- Publication type:
- Article
7
In Search of CML Stem Cells' Deadly Weakness.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 82, doi. 10.1007/s11899-011-0085-y
- By:
- Publication type:
- Article
8
The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 136, doi. 10.1007/s11899-011-0084-z
- By:
- Publication type:
- Article
9
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 104, doi. 10.1007/s11899-011-0083-0
- By:
- Publication type:
- Article
10
Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 145, doi. 10.1007/s11899-011-0086-x
- By:
- Publication type:
- Article
11
Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy.
- Published in:
- Current Hematologic Malignancy Reports, 2011, v. 6, n. 2, p. 88, doi. 10.1007/s11899-011-0087-9
- By:
- Publication type:
- Article